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The present study explored body mass index (BMI), height, and risk of prostate cancer in a large Norwegian cohort of 950000 men
aged 20–74 years, whose height and weight were measured in a standardised way in the period 1963–1999. These were followed
for an average of 21 years. The Cox proportional hazard models were used in the analyses. During follow-up, 33300 histologically
verified cases of prostate cancer were registered. The risk of prostate cancer increased by both BMI and height. The magnitude of the
increase by BMI was modest, the relative risk (RR) of obese men (BMIX30) compared with normal weighted was 1.09 (95% CI:
1.04–1.15). However, the RR at age 50–59 years was 1.58 (95% CI: 1.29–1.94) in men being obese at about age 45 years compared
with normal weighted men. The tallest men had an RR of 1.72 (95% CI: 1.46–2.04) compared with the shortest men. The overall
effect of BMI on the incidence of prostate cancer was modest. The larger effect found in men aged 50–59 years might partly explain
the previous inconsistent findings.
British Journal of Cancer (2003) 89, 1237–1242. doi:10.1038/sj.bjc.6601206 www.bjcancer.com
& 2003 Cancer Research UK
Keywords: prostate cancer; cohort study; Norway
                                      
Worldwide, prostate cancer is the third most common malignancy
in men with an estimated number of 500000 cases in the year 2000,
three-quarters in men aged 65 years or older (Parkin et al, 2001).
Around 1990, the incidence of prostate cancer increased in many
countries due to the introduction of widespread blood testing with
prostate-specific antigen (PSA) (Parkin et al, 2001). In Norway,
testing with PSA was introduced at the beginning of the 1990s
(Harvei, 1999).
The aetiology of prostate cancer is largely unknown (Hsing et al,
2001). However, hormonal relations, age, and race are known risk
factors. The relation between age and the incidence of prostate
cancer is especially strong. The large age-gradient, combined with
the ageing of many Western populations, will make prostate cancer
an increasing health problem.
Certain studies on body mass index (BMI) and prostate cancer
risk have concluded that there is no association (Bianchini et al,
2002). In a review of the literature up to 1998 (Bergstro ¨m et al,
2001), however, it was concluded that elevated BMI was associated
with the risk of prostate cancer. Overweight men (25oBMIo30;
BMI¼(weight in kilograms)/(height in metres)
2) had a 6%
increased risk compared with normal-weighted men (BMI 20–
25), while obese men (BMIX30) had a 12% increased risk. The
proportion of prostate cancer attributable to overweight and
obesity in European men was estimated to be 4% (Bergstro ¨m et al,
2001). A review of 12 case–control studies and 11 cohort studies
(Nomura, 2001), revealed the inconsistencies between studies on
this issue. If the relative risks (RRs) found by Bergstro ¨m et al are
close to the ‘real’ level, the increased risk of prostate cancer
associated with overweight/obesity is small. Large and well-
conducted studies are necessary to reveal increases in the risk of
this magnitude.
Also, the findings in studies on the association between height
and prostate cancer is inconsistent; two of nine cohort studies
found a significant positive association between height and
prostate cancer, but none of six case–control studies (Nomura,
2001).
The aim of the present study was to explore the relation between
height and BMI and the risk of prostate cancer in a large




During 1963–1975, height and weight were measured as part of a
screening programme aimed at detecting tuberculosis in the
general Norwegian population (Waaler, 1984; Bjartveit, 1997). This
mass examination was compulsory for persons aged 15 years and
older, and enrolled 1.7 million people. The attendance was about
85% in persons above the age of 15 years (Waaler, 1984). Previous
reports have described the impact of adults’ height and weight on
mortality (Waaler, 1984), and the material has also been utilised to
explore relations between BMI and cancer incidence (Helseth and
Tretli, 1989; Tretli, 1989; Tretli and Magnus, 1990; Thune et al,
1993; Robsahm and Tretli, 1999; Tretli and Robsahm, 1999). In
1963–1964 and in 1972–1999, height and weight were also
measured in health surveys in different parts of Norway (Bjartveit
et al, 1979; Bjartveit, 1997). The attendance in the mid-1970s was Received 7 April 2003; revised 24 June 2003; accepted 24 June 2003
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y85–90%, but decreased to about 75% in the mid-1990s (Bjartveit,
1997). The complete cohort has recently been used in a study of the
impact of height and BMI on mortality (Engeland et al, 2003).
The body weight (kilograms) was measured on scales that were
calibrated regularly, and registered to the nearest half kilogram.
Body height was measured and noted to the nearest centimetre.
The height was measured without shoes, and weight was measured
with the subject wearing light clothing. If the height and weight
measurements were performed under irregular circumstances, the
measurement was excluded (the persons were wearing shoes, the
persons were disabled, etc.). Further, measurements without
registered height or height below 120cm, or without registered
weight or weight below 20kg were excluded (67 measurements).
In the present study, the earliest accepted measurement between
age 20 and 75 years was used for each man. There were 952142
men with such measurements.
The study cohort was linked to the Death Registry at Statistics
Norway to follow all persons in the present study from the date of
measurement until eventual emigration or death. A unique 11-digit
identification number assigned to all individuals living in Norway
after 1960 simplified the linkage.
All cases of prostate cancer (International Classification of
Diseases, seventh revision (ICD-7): 177) in the study cohort were
identified by linkage to the Cancer Registry of Norway. Cancer
registration, covering the entire Norwegian population of about 4.5
million inhabitants (2002), was initiated in 1952, and reporting of
all diagnosed cancer cases has since been compulsory by law.
Notifications are independently issued by all clinical and pathology
departments involved in the diagnosis and treatment of cancer. In
addition, all death certificates with a mention of premalignant or
malignant disease reach the registry. The quality of the prostate
cancer data in the Cancer Registry of Norway has been assessed,
finding an error rate of about 1% of all data elements (Harvei et al,
1996).
In the present study, only histologically verified prostate cancer
diagnoses were included. Men with a prostate cancer diagnosis
prior to the height and weight measurements were excluded (676
men). The men in the cohort were followed up from the date of
measurement until date of prostate cancer diagnosis, emigration,
age 100 years, death, or until 30 June 2001. Altogether, 951466 men
were eligible for the study. A small number of these (seven men)
were lost to follow-up.
Statistical methods
The Cox proportional hazards regression models (Cox and Oakes,
1984), with time since measurement as time variable, were fitted to
obtain RR estimates of prostate cancer for different groups. In the
analyses, the following categorised variables were included:
(1) age at measurement: 20–24 years,y, 65–69 years, and 70–74
years.
(2) year of birth: o1900, 1900–1909,y, 1940–1949, and X1950.
(3) BMI ((weight in kilograms)/(height in metres)
2):
(a) detailed categorisation: BMI o18.50, 18.50–19.49,y,
22.50–23.49, 23.50–24.99, 25.00–27.49,y, 32.50–34.99,
and X35.00.
(b)WHO categorisation (World Health Organization Con-
sultation on Obesity, 1998): BMI o18.50 (underweight),
18.50–24.99 (normal range), 25.00–29.99 (preobese/over-
weight), and X30.00 (obese).
(4) height (cm): o160, 160–169, 170–179, 180–189, and X190.
Tests for linear trend were calculated by including BMI and
height, respectively, as continuous variables.
The proportionality assumption in the Cox model was assessed
by inspecting log-minus-log plots, results from stratified analyses,
and results from separate analyses for different intervals of
observation time. To explore whether BMI had a different impact
on prostate cancer in the different age groups, analyses stratified
on attained age and age at measurement were performed.
All analyses were carried out with the statistical program
package SPSS (SPSS Inc., 2001). The results were presented as RRs
of prostate cancer with 95% confidence intervals (CI).
RESULTS
A total of 951459 men (mean age: 44. 5 years) were followed for an
average of 21.0 years (range 0–38 years), comprising 20010705
person-years (Table 1). Among these, a total of 33314 prostate
cancer diagnoses were observed. The mean age at diagnosis was 73
years and the overall mean BMI was 24.9kgm
 2.
In men with BMI below 35.0kgm
 2, the risk of prostate cancer
was increasing with increasing BMI (Table 2), from an RR of 0.92
Table 1 Number of observed prostate cancer cases, person-years, and
overall prostate cancer rates
Variable Prostate cancer Person-years Cancer rate
a
Age at measurement
20–24 158 2242795 7
25–29 464 2255138 21
30–34 1054 2064155 51
35–39 2142 2233231 96
40–44 3798 3471729 109
45–49 5198 2411995 216
50–54 5539 1881942 294
55–59 5470 1448056 378
60–64 4432 1009951 439
65–69 3162 642324 492
70–74 1897 349388 543
Year of birth
o1900 2200 457438 481
1900–1909 7666 1733605 442
1910–1919 11117 3390484 328
1920–1929 8617 4723760 182
1930–1939 3071 4035564 76
1940–1949 611 4250296 14
X1950 32 1419558 2
Attained age
20–29 0 765591 0
30–39 3 2231577 0
40–49 126 4670388 3
50–59 1813 4752559 38
60–69 9511 4178645 228
70–79 15429 2645662 583
80–99 6432 766283 839
BMI (kgm
 2)
o18.50 147 130103 113
18.50–19.49 367 335470 109
19.50–20.49 914 790346 116
20.50–21.49 1778 1474133 121
21.50–22.49 2912 2215710 131
22.50–23.49 3766 2630649 143
23.50–24.99 6983 4248713 164
25.00–27.49 10001 5156901 194
27.50–29.99 4523 2107971 215
30.00–32.49 1453 672027 216
32.50–34.99 370 176482 210
X35.00 100 72201 139
Height (cm)
o160 245 138073 177
160–169 7091 3153938 225
170–179 19247 10958081 176
180–189 6421 5367993 120
X190 310 392620 79
Total 33314 20010705 166
aNumber of prostate cancer cases per 100000 person-years.
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yin men with BMI below 18.5kgm
 2 to 1.15 in men with BMI
32.5–34.9kgm
 2 compared with men with BMI 22.5–23.4kgm
 2
(reference group). An analysis stratified by age at measurement
revealed that the excess risk of prostate cancer in obese men was
roughly of similar magnitude irrespective of age at measurement
(Table 3). However, an indication of higher obesity-associated risk
was seen in those being youngest at measurement. Men measured
at the age of 20–29 years were younger than 70 years at the end of
follow-up. In the analyses stratified by attained age (Table 4), the
RR of prostate cancer in age 50–59 years for obese men (measured
at an average age of 45 years) was 1.58 (95% CI: 1.29–1.94)
compared with men with BMI within the ‘normal range’.
An increasing risk of prostate cancer with increasing height was
observed (Table 2). The tallest men had an RR of 1.72 (95% CI:
1.46–2.04) compared with the shortest men. The mean height was
increasing with increasing birth year from 170cm for men born
around 1890 to 180cm in those born around 1975 (mean annual
increase: 0.12cm). However, including men born before 1930 gave
almost identical results with regard to the impact of both BMI and
height on the risk of prostate cancer.
In order to reduce the potential effect of persisting disease at the
weight measurement, analyses were performed with exclusion of
the first 5 years of follow-up. This exclusion did not change the
results. Since PSA testing was introduced around 1990, leading to
an increase in the registered incidence of prostate cancer in
Norway, analyses were performed using 31 December 1989 as the
final date for the end of follow-up. Similar results were obtained.
Use of age-specific quintiles of height, weight, and BMI instead
of the categorisation used above showed monotonely increasing
risk of prostate cancer by increasing quintile. Compared with the
lowest quintile, the highest quintile of height, weight, and BMI had
RRs of 1.20 (95% CI: 1.16–1.25), 1.22 (95% CI: 1.18–1.26), and
1.13 (95% CI: 1.09–1.17), respectively.
DISCUSSION
In the present study, height and weight were measured in 950000
men, and these men were successively followed for an average of
21 years with respect to incidence of prostate cancer. An increasing
risk of prostate cancer was observed both with increasing BMI and
height.
Our study subjects were recruited from population-based
studies with high attendance, and the measurements were
performed in a standardised way. Use of a unique identification
number and population-based registries on deaths, emigrations,
and cancer incidence ascertained an almost complete follow-up of
the study subjects (951466 men). Only seven men were lost to
follow-up. By the end of follow-up, 58.3% of the men were alive
without a diagnosis of prostate cancer (0.9% of these had
emigrated from Norway), 38.2% were dead, and 3.5% had a
diagnosis of prostate cancer.
The present study is, to our knowledge, the largest study issued
to explore the relation between height/BMI and prostate cancer,
allowing a more detailed categorisation than in previous studies.
The largest study so far on the association between BMI and
prostate cancer (Rodriguez et al, 2001) included 820000 men. The
data were from the American Cancer Prevention Study I and II
Table 2 Relative risk (RR) of prostate cancer with 95% confidence
intervals (CI) from Cox regression analysis; age at measurement and birth
cohort were included in the model in addition to either one of the
categorisations of body mass index (BMI) or height





o18.50 147 0.92 0.78–1.08
18.50–24.99 16720 1.00 Referent
25.00–29.99 14524 1.07 1.05–1.09
X30.00 1923 1.09 1.04–1.15
BMI (kgm
 2)
o18.50 147 0.92 0.78–1.08
18.50–19.49 367 0.91 0.81–1.01
19.50–20.49 914 0.95 0.88–1.02
20.50–21.49 1778 0.94 0.89–1.00
21.50–22.49 2912 0.97 0.93–1.02
22.50–23.49 3766 1.00 Referent
23.50–24.99 6983 1.04 1.00–1.09
25.00–27.49 10001 1.07 1.03–1.11
27.50–29.99 4523 1.07 1.02–1.12
30.00–32.49 1453 1.09 1.03–1.16
32.50–34.99 370 1.15 1.03–1.28
X35.00 100 0.93 0.76–1.13 Po0.001
Height (cm)
o160 245 0.64 0.57–0.73
160–169 7091 0.89 0.87–0.92
170–179 19247 1.00 Referent
180–189 6421 1.06 1.03–1.09
X190 310 1.11 0.99–1.24 Po0.001
aBMI and height, respectively, were included as continuous variables.
Table 3 Relative risk (RR) of prostate cancer from the Cox regression analysis with 95% confidence intervals (CI) by age at measurement and body mass
index (BMI) or height, adjusted for birth cohort
Age at measurement (years)
20–29 (622 cases) 30–39 (3196 cases) 40–49 (8996 cases) 50–59 (11009 cases) 60–69 (7594 cases) 70–74 (1897 cases)
Variable RR 95% CI RR 95% CI RR 95% CI RR 95% CI RR 95% CI RR 95% CI
BMI (kgm
 2)
o18.50 0.93 0.41–2.08 1.02 0.59–1.76 0.72 0.48–1.09 0.77 0.55–1.08 1.17 0.90–1.51 0.53 0.29–0.99
18.50–24.99 1.00 Referent 1.00 Referent 1.00 Referent 1.00 Referent 1.00 Referent 1.00 Referent
25.00–29.99 1.20 1.00–1.44 1.06 0.99–1.14 1.06 1.02–1.11 1.09 1.05–1.14 1.08 1.03–1.13 1.08 0.98–1.18
X30.00 1.22 0.69–2.17 1.19 0.99–1.44 1.05 0.95–1.16 1.05 0.97–1.14 1.14 1.04–1.24 1.04 0.87–1.23
Height (cm)
o160 0.56 0.08–3.97 0.42 0.18–1.02 0.52 0.35–0.78 0.70 0.56–0.88 0.65 0.54–0.80 0.60 0.43–0.83
160–169 0.73 0.53–1.01 0.91 0.81–1.03 0.91 0.85–0.97 0.90 0.86–0.95 0.91 0.86–0.95 0.87 0.79–0.95
170–179 1.00 Referent 1.00 Referent 1.00 Referent 1.00 Referent 1.00 Referent 1.00 Referent
180–189 1.14 0.97–1.35 1.04 0.96–1.12 1.04 0.99–1.09 1.02 0.97–1.08 1.10 1.02–1.19 1.16 0.97–1.37
X190 0.62 0.34–1.13 1.12 0.89–1.42 1.18 1.00–1.40 1.08 0.85–1.38 1.00 0.64–1.58 0.00 0.00–N
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y(CPS-I and CPS-II), and included 5200 prostate cancer deaths. A
Swedish study (Andersson et al, 1997) included 2400 incident cases
of prostate cancer and 700 deaths from prostate cancer. The
present study included 33300 incident cases.
The large study size made it possible to perform a number of
stratified analyses, with high statistical power, which has not been
possible in other studies on this issue. However, the stratified
analyses were performed without having any specific hypothesis in
advance. Therefore, the results must be interpreted with caution.
The findings may be chance findings.
A stratified analysis by attained age revealed that there was a
marked increased risk of prostate cancer in obese men compared
with normal weighted men at age 50–59 years, while the RR in
older age groups were modest. Since the incidence of prostate
cancer is much higher at older ages, this effect, if it is real,
will be hidden in studies where much of the total observation
time is above this age. This might explain some of the
inconsistencies between previous studies. In a recent review
(Nomura, 2001), two of 10 cohort studies revealed a positive
association between BMI and prostate cancer. These two studies
(Andersson et al, 1997; Veierd et al, 1997) included relatively
young populations. In one study (Veierd et al, 1997), using a
subcohort of the present study (o3% of the men, o2% of the
person-years), 91% of the person-years and 42% of the cases were
less than 60 years. In the other study (Andersson et al, 1997), the
association between BMI and both incidence of and mortality from
prostate cancer was studied in a cohort of 135000 Swedish
construction workers followed for an average of 18 years; 53% of
the men were below age 60 years during the entire follow-up
period and additional 19% were below 60 years in most of the
follow-up period. The association between BMI and prostate
cancer was stronger when looking at mortality than at
incidence. The study by Rodriguez et al (2001), not being included
in the review by Nomura, found a positive association between
BMI and prostate cancer mortality in both study cohorts. In CPS-I
and CPS-II, the men had median age of between 52 and 57 years,
respectively. The average follow-up was 12 years. In another study
(Thune and Lund, 1994), not included in the review by Nomura, an
increased risk of prostate cancer by increasing BMI in a cohort
using parts of the present study cohort (o5% of the men, o3% of
the person-years) was found. Also in this cohort, the men were
relatively young with a median age at prostate cancer diagnosis of
61 years.
The four largest cohort studies reviewed by Nomura (2001),
which did not find an association between BMI and prostate
cancer, seemed to include a larger proportion of person-years
above the age of 60 years than in the studies that found positive
associations. In a Dutch study (Schuurman et al, 2000), 55–69-
year-old men were followed for an average of 6 years. The median
age at diagnosis was 70 years in the study by Habel et al (2000).
Giovannucci et al (1997) followed 40–75-year-old men for an
average of 7 years. A Norwegian study (Nilsen and Vatten, 1999),
using a subcohort of the present study (2% of the men, 1% of the
person-years), included men with a mean age of 59 years at the
start of follow-up.
The majority of prostate cancer cases occur in men above the
age of 60 years. However, the relative increase in prostate cancer
incidence is higher in men aged 50–59 years than in other age
groups both in the US as well as in other countries (Hsing et al,
2000). This can be both due to differences in screening practices by
age, and the increasing proportion of obese men, suggested by an
increased risk due to obesity in this age group in the present study.
Use of the Cox proportional hazards regression models assumes
that RRs do not vary by time. The present finding of a somewhat
different impact of obesity on the risk of prostate cancer at age 50–
59 years violates the proportionality assumption in the Cox model.
Restricting the analysis to ages above 60 years gave similar results
as the main analysis, due to the low number of prostate cancer
cases under the age of 60 years.
Some of the strengths of the present study were that height and
weight were measured in various ages over a wide age-span and the
long follow-up. Hence, we could adjust for age at measurement in
the analyses. However, men being 80–99 years during the follow-
up period had an average age at measurement of 60 years and only
11% were less than 50 years old. A possible explanation for a
decreasing RR by attained age is that certain levels of BMI may
have different meaning in young age and older age. However,
persons with a BMI above 30 generally have a high percentage of
fat, irrespective of age.
Some studies have looked at mortality from prostate cancer
instead of incidence (Andersson et al, 1997; Rodriguez et al, 2001).
Decreased survival among obese men has been suggested as an
explanation for the stronger association between BMI and prostate
cancer mortality (Rodriguez et al, 2001). Previous studies of the
impact of BMI on the incidence of prostate cancer have been
inconsistent, while studies on prostate cancer mortality have more
consistently shown increased risk associated with obesity (Ro-
driguez et al, 2001). In the present study, we studied cancer
incidence with the inclusion of histologically verified prostate
cancers only.
Table 4 Relative risk (RR) of prostate cancer from the Cox regression analysis with 95% confidence intervals (CI) by attained age and body mass index
(BMI) or height, adjusted for birth cohort and age at measurement
a
Attained age (years)
50–59 (1813 cases) 60–69 (9511 cases) 70–79 (15429 cases) 80–99 (6432 cases)
Variable RR 95% CI RR 95% CI RR 95% CI RR 95% CI
BMI (kgm
 2)
o18.50 0.82 0.41–1.65 0.89 0.65–1.22 0.80 0.62–1.02 1.05 0.76–1.47
18.50–24.99 1.00 Referent 1.00 Referent 1.00 Referent 1.00 Referent
25.00–29.99 1.13 1.02–1.25 1.04 1.00–1.09 1.07 1.04–1.11 1.07 1.02–1.13
X30.00 1.58 1.29–1.94 1.00 0.91–1.10 1.07 1.00–1.14 1.04 0.93–1.15
Height (cm)
o160 0.45 0.17–1.19 0.45 0.32–0.64 0.70 0.59–0.82 0.63 0.50–0.79
160–169 0.83 0.72–0.97 0.88 0.83–0.93 0.92 0.89–0.96 0.84 0.80–0.89
170–179 1.00 Referent 1.00 Referent 1.00 Referent 1.00 Referent
180–189 1.03 0.92–1.14 1.09 1.04–1.15 1.07 1.02–1.11 1.02 0.95–1.11
X190 0.85 0.60–1.21 1.33 1.13–1.56 1.01 0.83–1.24 1.03 0.66–1.60
aMean age at measurement (minimum–maximum) in the different strata: 50–59: 41 years (20–60); 60–69: 49 years (22–70); 70–79: 55 years (32–75); 80–99: 60 years
(42–75).
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yThe results of the present study on the relation between BMI and
risk of prostate cancer were consistent with the estimates given by
Bergstro ¨m et al (2001). Use of the same intervals of BMI
(BMIo20.0, 20.0–24.9, 25.0–29.9, and X30.0) as Bergstro ¨m et al,
gave RRs of 1.07 (95% CI: 1.04–1.09) for men with BMI 25–29 and
1.09 (95% CI: 1.04–1.14) for men with BMI above 30kgm
 2
compared with those having BMI 20–24kgm
 2.
Even though only two of the nine cohort studies included in the
review by Nomura (2001) found a significant positive association
between height and prostate cancer, seven of the eight studies with
an RR for height had RRs above one. Four (Andersson et al, 1997;
Veierd et al, 1997; Nilsen and Vatten, 1999; Habel et al, 2000) of
the six largest studies (Andersson et al, 1997; Giovannucci et al,
1997; Veierd et al, 1997; Nilsen and Vatten, 1999; Habel et al,
2000; Schuurman et al, 2000) found a 10–20% higher risk of
prostate cancer in the highest quintile or quartile compared with
the lowest. One study (Giovannucci et al, 1997) found an RR of 1.4
in the highest category compared with the lowest, while one study
did not find any association at all (Schuurman et al, 2000). More
recently, a positive association has been observed in CPS-I, but not
in CPS-II (Rodriguez et al, 2001). In the present study, a markedly
increased risk was found in the highest compared with the lowest
men. The low risk connected to the shortest men can partly be
explained by low incidence in the shortest men in the two
northernmost counties in Norway. These two counties have a
relatively large proportion of Lapps, who are generally short and
have a low incidence of prostate cancer (Baste et al, 1992; Harvei,
1999). Categorising height by quintiles instead of the first chosen
categorisation gave an RR of 1.20 (95% CI: 1.16–1.25) when
comparing the highest with the lowest quintile. Excluding the two
northernmost counties gave a slightly lower RR (RR¼1.17; 95%
CI: 1.13–1.21). The biological mechanisms underlying a possible
association between height and prostate cancer are uncertain
(Gunnell et al, 2001). A possible explanation is that height acts as a
marker for the levels of insulin-like growth factors (IGFs) (Gunnell
et al, 2001). An increased risk of prostate cancer has been observed
in men with elevated plasma insulin-like growth factor-I (IGF-I)
(Chan et al, 1998; Stattin et al, 2000).
In summary, in this large Norwegian cohort both height
and BMI were positively associated with the risk of
prostate cancer. The overall magnitude of the increase in risk
of prostate cancer by increasing BMI was modest. However,
in the age group 50–59 years, obese men had 58% higher risk
than normal weighted men. The larger effect in this age group
might partially explain the previous inconsistent findings.
Even though the overall increased prostate cancer risk by BMI is
minor, the large incidence of prostate cancer in older men in
combination with the increasing BMI in many Western popula-
tions will increase the future importance of BMI as a risk factor for
prostate cancer.
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